IGF1R and thromboangiitis obliterans: TSHR signal mediation partly depends on functional IGF-1R, and the human IGF-1R inhibitory monoclonal antibody teprotumumab is a breakthrough advancement in TAO treatment (Smith et al., 2017; Douglas et al., 2020).